Measurable imaging-based changes in enhancement of intrahepatic cholangiocarcinoma after radiotherapy reflect physical mechanisms of response.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
De Brian, Dogra Prashant, Zaid Mohamed, Elganainy Dalia, Sun Kevin, Amer Ahmed M, Wang Charles, Rooney Michael K, Chang Enoch, Kang Hyunseon C, Wang Zhihui, Bhosale Priya, Odisio Bruno C, Newhook Timothy E, Tzeng Ching-Wei D, Tran Cao Hop S, Chun Yun S, Vauthey Jean-Nicholas, Lee Sunyoung S, Kaseb Ahmed, Raghav Kanwal, Javle Milind, Minsky Bruce D, Noticewala Sonal S, Holliday Emma B, Smith Grace L, Koong Albert C, Das Prajnan, Cristini Vittorio, Ludmir Ethan B, Koay Eugene J
Аннотация
Escalated doses of radiotherapy associate with improved local control and overall survival (OS) in intrahepatic cholangiocarcinoma (iCCA), but personalization remains limited because conventional size-based CT criteria correlate poorly with outcomes. We hypothesized that quantitative enhancement measurements would better predict clinical outcomes and guide individualized RT optimization. In a retrospective cohort of 154 patients, we analyzed pre- and post-RT CT scans using quantitative European Association for Study of Liver (qEASL) to derive viable tumor volumes, comparing enhancement-based metrics with size-based RECIST and linking them to outcomes via survival and mathematical modeling. Change in enhancement volume was strongly associated with OS after adjustment, outperforming RECIST, and a ≥ 33% reduction optimally distinguished responders. From modeling analyses, the patient-specific tumor growth rate parameter emerged as the dominant mechanistic predictor, achieving 80.5% classification accuracy. Importantly, CT-derived mathematical parameters from this framework may inform RT planning and dose adaptation, particularly for resistant tumors, by bridging imaging with mechanistic insight.